PALVELLA THERAPEUTICS, INC.
PVLA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PVLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PVLA
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare diseases, with its lead candidate under FDA review for microcystic LM and a cash position of $187.8M as of June 30, 2025.
Key risk: No product revenue or profitability
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for PALVELLA THERAPEUTICS, INC..
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare diseases, with its lead candidate under FDA review for microcystic LM and a cash position of $187.8M as of June 30, 2025.
- Lead product candidate QTORIN rapamycin is under FDA review for the treatment of microcystic LM [sec_mda · as of 2026-08-04].
- Cash and equivalents of $187.8M as of June 30, 2025 [sec].
- Net loss of $21.9M for the period ending June 30, 2025 [sec].
- Shareholders' equity of $28.0M as of June 30, 2025 [sec].
- Company expects losses to increase as it advances product candidates through clinical trials and regulatory submissions [sec_mda · as of 2026-05-07].
What works
- Lead candidate QTORIN rapamycin is under FDA review for microcystic LM, a potential near-term regulatory catalyst [sec_mda · as of 2026-08-04].
- Cash position of $187.8M as of June 30, 2025 provides a multi-year runway to fund operations and development [sec].
- Company is building a commercial organization in preparation for a potential launch of QTORIN rapamycin [sec_mda · as of 2026-08-04].
What to weigh
- Company has not generated product revenue or achieved profitability and expects to continue incurring net losses [sec_mda · as of 2025-03-31].
- Development costs are uncertain and may be significantly higher than anticipated due to reliance on third-party contractors and regulatory timelines [sec_mda · as of 2026-08-04].
- Accumulated deficit and ongoing losses may require additional financing to complete development and commercialization [sec_mda · as of 2025-03-31].
From the filings
Quoted directly from source documents.
QTORIN rapamycin is under FDA review for microcystic LM.
“commercial organization in preparation for the launch of our lead product candidate, QTORIN rapamycin for the treatment of microcystic LM, which is currently under review at the FDA”
SEC MD&A · August 4, 2026
Company expects losses to increase as it advances product candidates.
“losses to increase as we continue to advance our product candidates through clinical trials and regulatory submissions”
SEC MD&A · May 7, 2026
Risks & what to watch (4)›
Key risks
- No product revenue or profitability — Company has not generated product revenue and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2025-03-31].
- Uncertain development costs — Duration and costs of clinical trials may be significantly higher than anticipated due to reliance on third-party contractors [sec_mda · as of 2026-08-04].
- Need for additional financing — Company may need to raise additional capital to fund operations, complete development, and commercialize product candidates [sec_mda · as of 2025-03-31].
- Regulatory and commercial risks — FDA review outcome for QTORIN rapamycin is uncertain; commercial launch depends on approval and market acceptance [sec_mda · as of 2026-08-04].
What to watch
- FDA decision on QTORIN rapamycin for microcystic LM, a key regulatory milestone [sec_mda · as of 2026-08-04].
- Progress of clinical trials for QTORIN rapamycin in venous malformations and other indications [sec_mda · as of 2025-03-31].
- Cash burn rate and any updates on financing needs or additional capital raises [sec].
- Updates on commercial organization buildout and launch preparations [sec_mda · as of 2026-08-04].
Sources: SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run PALVELLA THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PALVELLA THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
58.0 months
D/E 0.17 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
1 buy · 23 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
182
Total value held
$1.53B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 1,153,496 | $143.8M |
| bvf inc/il | 960,989 | $119.8M |
| vanguard capital management llc | 954,588 | $119.0M |
| blackrock, inc. | 686,853 | $85.6M |
| jennison associates llc | 640,611 | $79.9M |
| woodline partners lp | 635,034 | $79.2M |
| state street corp | 458,999 | $57.2M |
| federated hermes, inc. | 433,015 | $54.0M |
| frontier capital management co llc | 374,035 | $46.6M |
| siren, l.l.c. | 257,485 | $32.1M |
Showing top 10 of 182 institutional holders of PALVELLA THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 17.2%
- Days to cover
- 9.1
- Shares short
- 2,170,623
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PVLA short interestGovernance
Frequently asked questions
What is the AI investment thesis for PALVELLA THERAPEUTICS, INC.?
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare diseases, with its lead candidate under FDA review for microcystic LM and a cash position of $187.8M as of June 30, 2025.
What is PALVELLA THERAPEUTICS, INC.'s lead drug candidate?
PALVELLA THERAPEUTICS, INC.'s most advanced tracked candidate is qtorin rapamycin (Phase 3) for Cutaneous Venous Malformations; Microcystic Lymphatic Malformation.
Who is the CEO of PALVELLA THERAPEUTICS, INC.?
Mr. Wesley H. Kaupinen is the chief executive officer of PALVELLA THERAPEUTICS, INC. (PVLA).
Where is PALVELLA THERAPEUTICS, INC. headquartered?
PALVELLA THERAPEUTICS, INC. (PVLA) is headquartered in Wayne, PA, United States.
What therapeutic areas does PALVELLA THERAPEUTICS, INC. focus on?
PALVELLA THERAPEUTICS, INC. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.